Stockscreener 앱 받기
0.8037
2.29%
-0.0188
시간 외 거래:
.79
-0.0137
-1.70%
Tenaya Therapeutics Inc 주식(TNYA)의 최신 뉴스
TNYA pulls back after hours following significant $1.13B deal-spurred rally - MSN
Alnylam’s research pact worth up to $1.1B sends Tenaya higher - MSN
symbol__ Stock Quote Price and Forecast - CNN
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Tenaya Therapeutics (NASDAQ:TNYA) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
How TN-301 Progress And Alnylam Deal At Tenaya Therapeutics (TNYA) Has Changed Its Investment Story - simplywall.st
What is Lifesci Capital's Estimate for TNYA Q1 Earnings? - MarketBeat
Outperform Maintained on Tenaya Therapeutics (TNYA) by Leerink and William Blair March 2026 - Meyka
Tenaya Therapeutics (TNYA) Valuation After TN-301 Data And New Alnylam Collaboration - simplywall.st
William Blair reiterates Outperform on Tenaya Therapeutics stock - Investing.com Australia
William Blair reiterates Outperform on Tenaya Therapeutics stock By Investing.com - Investing.com South Africa
Leerink Partners reiterates Outperform on Tenaya stock at $2 - Investing.com UK
Chardan Capital Reiterates Buy Rating for Tenaya Therapeutics (NASDAQ:TNYA) - MarketBeat
Tenaya Therapeutics Reports Promising 2025 Results, Advances Gene Therapy Programs, and Extends Cash Runway Into 2027 - Minichart
Tenaya Therapeutics (TNYA) Is Up 47.7% After Positive TN-301 DMD Data And Alnylam Deal - Yahoo Finance
Tenaya Therapeutics: Advancing Genetic Medicines and Small Molecule Therapies for Heart Disease Treatment - Minichart
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Bitget
Tenaya Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Tenaya Therapeutics' Q4 net loss narrows, extends cash runway into H2 2027 - TradingView
Tenaya Therapeutics (NASDAQ:TNYA) Issues Earnings Results, Meets Expectations - MarketBeat
Tenaya Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
TNYA: Clinical progress, Alnylam deal, and financing extend cash runway into 2027 - TradingView
Tenaya Therapeutics (NASDAQ: TNYA) narrows 2025 loss and extends cash runway to 2027 - Stock Titan
Q4 and 2025 results drive business momentum, Tenaya Therapeutics outlines - Traders Union
BRIEF-Tenaya Therapeutics Q4 Net Income USD -20.175 Million Vs. IBES Estimate USD -22 Million - TradingView
Heart gene therapy data and $1.1B Alnylam deal help Tenaya fund work to 2027 - Stock Titan
Tenaya Therapeutics Soars with Major Collaboration Deal - timothysykes.com
Tenaya Therapeutics Reports TN-301 Outperforms Givinostat in Enhancing Muscle Function and Addressing DMD Cardiomyopathy - Quiver Quantitative
Experimental drug TN-301 restores muscle strength in Duchenne mice - Stock Titan
Tenaya Therapeutics Presents Preclinical Data at MDA 2026 - GlobeNewswire
Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301's Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy - Bitget
Leerink Partners Global Biopharma Conference 2026: TEVA, CYTK, IMRX, TNYA And More Set To Present - RTTNews
Morgan Stanley reduces PT on Tenaya Therapeutics (TNYA), keeps constructive stance on US small- to mid-cap biotech - MSN
Tenaya Therapeutics, Inc.Common Stock (NQ: TNYA - The Chronicle-Journal
Assessing Alnylam Pharmaceuticals (ALNY) Valuation After New Cardiovascular Partnership With Tenaya Therapeutics - simplywall.st
Tenaya Therapeutics announces orderly board leadership transition - MSN
Lifesci Capital Upgrades Tenaya Therapeutics (NASDAQ:TNYA) to Strong-Buy - MarketBeat
Hedge Fund Bets: Can Tenaya Therapeutics Inc lead its sector in growth2025 Market Sentiment & Precise Swing Trade Alerts - baoquankhu1.vn
Tenaya, Alnylam join in $1B+ cardio deal for novel genetic targets - BioWorld MedTech
Tenaya Therapeutics inks $1 billion-plus research deal with Alnylam - The Pharma Letter
Tenaya Therapeutics Stock Jumps After New Alnylam Deal - Sahm
TNYA Pulls Back After Hours Following Significant $1.13B Deal-Spurred Rally - Asianet Newsable
Tenaya To Evaluate Genetic Cardiovascular Targets For Alnylam - Citeline News & Insights
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Tenaya wins support from Alnylam in cardio disease pact - Endpoints News
Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments - marketscreener.com
Tenaya Therapeutics Signs Potential $1.13 Billion Deal With Alnylam - marketscreener.com
Tenaya Therapeutics Announces Major Cardiovascular Gene Target Collaboration - TipRanks
Tenaya Therapeutics enters into research collaboration with Alnylam Pharmaceuticals to identify and validate novel genetic targets for cardiovascular disease therapeutics - marketscreener.com
Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics - The Manila Times
1.20%
0.06%
자본화:
|
볼륨(24시간):